[2-(3-amino-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester | 896114-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-(3-amino-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester
• 英文别名: propan-2-yl N-[2-(3-aminophenyl)-1H-imidazo[4,5-b]pyridin-6-yl]carbamate
• CAS: 896114-05-9
• 化学式: C₁₆H₁₇N₅O₂
• 分子量: 311.343
• InChiKey: XLQARXUCBQXQSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [2-(3-amino-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester 、 乙酰氯 在 甲醇 、 氨 作用下， 以 吡啶 为溶剂， 反应 1.0h， 生成 [2-(3-acetylamino-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester
  参考文献：
  名称：

  Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents

  摘要：

  本发明的对象是公式I化合物及其药学上可接受的盐、对映体、非对映异构体和混合物，上述化合物的制备、含有它们的药物以及它们的制造，以及上述化合物在控制或预防癌症等疾病中的使用。

  公开号：

  US07786113B2
• 作为产物：
  描述：

  [2-(3-Nitro-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 0.75h， 生成 [2-(3-amino-phenyl)-3H-imidazo[4,5-b]pyridin-6-yl]-carbamic acid isopropyl ester
  参考文献：
  名称：

  Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents

  摘要：

  本发明的对象是公式I的化合物，它们的药学上可接受的盐、对映体形式、二对映异构体和消旋体，上述化合物的制备，含有它们的药物以及其制造，以及上述化合物在控制或预防癌症等疾病中的应用。

  公开号：

  US20080009492A1

文献信息

• CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1831218A2

  公开（公告）日：2007-09-12
• METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161A2

  公开（公告）日：2015-05-20
• DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161B1

  公开（公告）日：2020-12-16
• METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR
  申请人：Del Mar Pharmaceuticals (BC) Ltd.

  公开号：US20210251944A1

  公开（公告）日：2021-08-19

  Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI-1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI-1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI-1 gene or AHI-1 protein, and the compositions can further include such an agent.
• US7786113B2
  申请人：——

  公开号：US7786113B2

  公开（公告）日：2010-08-31